Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:37:47 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:ATOS from 2023-04-27 to 2024-04-26 - 43 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-15 08:30U:ATOSNews ReleaseAtossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO(TM)) in Women with ER+/HER2- Breast Cancer
2024-04-11 08:30U:ATOSNews ReleaseAtossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
2024-04-09 11:59U:ATOSNews ReleaseAtossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
2024-04-01 16:00U:ATOSNews ReleaseAtossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
2024-03-19 08:30U:ATOSNews ReleaseAtossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
2024-03-18 08:30U:ATOSNews ReleaseAtossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
2024-03-12 08:30U:ATOSNews ReleaseAtossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
2024-03-06 08:30U:ATOSNews ReleaseData from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
2024-02-22 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
2024-02-07 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Full Enrollment of ‚  (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
2024-01-09 08:30U:ATOSNews ReleaseAtossa Therapeutics Issues Letter to Shareholders
2023-12-04 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
2023-11-20 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
2023-11-13 09:00U:ATOSNews ReleaseAtossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-09 09:00U:ATOSNews ReleaseAtossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
2023-10-30 13:00U:ATOSNews ReleaseQuantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
2023-10-11 08:30U:ATOSNews ReleaseFast-food consumption by adolescent girls may sow the seeds of breast cancer decades later
2023-09-18 11:14U:ATOSNews ReleaseApproximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
2023-09-18 11:12U:ATOSNews ReleaseApproximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
2023-09-18 08:30U:ATOSNews ReleaseAtossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
2023-08-23 08:01U:ATOSNews ReleaseAtossa Therapeutics backing Endoxifen in the fight against breast cancer
2023-08-14 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
2023-08-08 09:00U:ATOSNews ReleaseAtossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023
2023-07-20 09:15U:ATOSNews ReleaseAtossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada
2023-07-13 16:15U:ATOSNews ReleaseAtossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
2023-07-12 09:02U:ATOSNews Release50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
2023-07-10 09:15U:ATOSNews ReleaseAtossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
2023-07-06 09:15U:ATOSNews ReleaseAtossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer
2023-06-28 13:03U:ATOSNews ReleaseAtossa Therapeutics announces 30% enrollment for Phase 2 I-Spy breast cancer clinical trial
2023-06-28 09:15U:ATOSNews ReleaseAtossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
2023-06-28 09:15U:ATOSNews ReleaseAtossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
2023-06-27 09:15U:ATOSNews ReleaseAtossa Therapeutics Announces $10M Stock Repurchase Program
2023-06-22 16:15U:ATOSNews ReleaseAtossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023
2023-06-21 13:49U:ATOSNews ReleaseAtossa Therapeutics announces further patent protection for Endoxifen
2023-06-21 10:14U:ATOSNews ReleaseAtossa Therapeutics Granted Additional Patent Protection for Endoxifen
2023-06-14 09:15U:ATOSNews ReleaseAtossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC
2023-06-12 09:15U:ATOSNews ReleaseAtossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
2023-06-01 09:10U:ATOSNews ReleaseAtossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
2023-05-23 07:00U:ATOSNews ReleaseSocietal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator
2023-05-15 09:10U:ATOSNews ReleaseAtossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
2023-05-11 09:00U:ATOSNews ReleasePhysician-Scientist Dr. Steven Quay Provides Recommendations to the United States Preventive Services Task Force on Breast Cancer Screening Policies and Practices
2023-05-09 09:15U:ATOSNews ReleaseAtossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
2023-04-27 09:15U:ATOSNews ReleaseAtossa Therapeutics to Participate in Tribe Public ¢ € ™s Webinar Event ‚   ¢ € œRedefining Breast Cancer Prevention and Treatment ¢ € 